Entocort™(budesonide) is a first-line anti-inflammatory agent and locally acting glucocorticosteroid indicated for the induction and maintenance of remission of mild to moderate ileocaecal Crohn’s disease (capsules) and ulcerative colitis (enemas) as well as for the remission of active microscopic colitis (capsules). Entocort™ is available in two formulations, capsule and enema, and is available in more than 40 countries. Specific indications and instructions for use vary by country.
Last update: October 2017.
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, Octasa™, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™ and Budecol™ and are either registered or applied for in up to 70 countries. The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries (transfer of market authorisations to Tillotts in process) except for the USA.
Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.